32 articles for JJ Edmunds
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-car
Warner-Lambert
Discovery of selective and orally bioavailable protein kinase C¿ (PKC¿) inhibitors from a fragment hit.
Abbvie Bioresearch Center
Optimized protein kinase C¿ (PKC¿) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.
Abbvie Bioresearch Center
Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.
Pfizer
The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex--Part 2.
Pfizer
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.
Pfizer
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.
Pfizer
Benzyl ether structure-activity relationships in a series of ketopiperazine-based renin inhibitors.
Pfizer
Equipotent activity in both enantiomers of a series of ketopiperazine-based renin inhibitors.
Pfizer
Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors.
Shire Biochem
Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.
Shire Biochem
Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
Biochem Pharma
Rational design, synthesis, and biological activity of benzoxazinones as novel factor Xa inhibitors.
Pfizer
The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 2.
Warner-Lambert
The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 1.
Warner-Lambert
Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications.
Warner-Lambert
Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.
Warner-Lambert
Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.
Biochem Therapeutic
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
Warner-Lambert
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.
Warner-Lambert
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonists.
Warner-Lambert
